Acetaminophen toxicity: Difference between revisions
(Major update: Rumack-Matthew nomogram use, IV/PO NAC protocols, 2-bag protocol, King College Criteria, when to stop NAC, NAPQI mechanism, risk factors, anaphylactoid management, references with PMIDs) |
(Strip excess bold) |
||
| Line 2: | Line 2: | ||
*'''Most common cause of acute liver failure''' in the United States and UK | *'''Most common cause of acute liver failure''' in the United States and UK | ||
*Found in >600 OTC and prescription products (Tylenol, Percocet, Vicodin, NyQuil, etc.) | *Found in >600 OTC and prescription products (Tylenol, Percocet, Vicodin, NyQuil, etc.) | ||
* | *Therapeutic dose: 10-15 mg/kg per dose (max 4g/day in adults; 2g/day in chronic alcoholics) | ||
* | *Toxic dose: >150 mg/kg (single ingestion) or > 7.5 g total in adults | ||
*Mechanism: | *Mechanism: | ||
**Normal metabolism: 90% glucuronidation/sulfation → nontoxic → renally excreted | **Normal metabolism: 90% glucuronidation/sulfation → nontoxic → renally excreted | ||
**~5% oxidized by CYP2E1 → | **~5% oxidized by CYP2E1 → NAPQI (toxic metabolite) → detoxified by glutathione | ||
**In overdose: glucuronidation/sulfation saturated → excess NAPQI production → | **In overdose: glucuronidation/sulfation saturated → excess NAPQI production → glutathione depletion → hepatocellular necrosis | ||
* | *N-acetylcysteine (NAC) is a glutathione precursor and is nearly 100% effective when given within 8 hours of ingestion<ref>Smilkstein MJ, et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. ''N Engl J Med''. 1988;319(24):1557-1562. PMID 3059186</ref> | ||
===Risk Factors for Enhanced Toxicity=== | ===Risk Factors for Enhanced Toxicity=== | ||
| Line 14: | Line 14: | ||
*Fasting / malnutrition (depleted glutathione) | *Fasting / malnutrition (depleted glutathione) | ||
*CYP2E1 inducers: isoniazid, phenobarbital, carbamazepine, rifampin | *CYP2E1 inducers: isoniazid, phenobarbital, carbamazepine, rifampin | ||
* | *Lower threshold for treatment in these patients | ||
==Clinical Features== | ==Clinical Features== | ||
===Four Stages of Toxicity=== | ===Four Stages of Toxicity=== | ||
* | *Stage 1 (0-24h): Often asymptomatic or nonspecific (nausea, vomiting, anorexia, diaphoresis) | ||
* | *Stage 2 (24-72h): RUQ pain, elevated transaminases, rising INR; may appear to improve clinically | ||
* | *Stage 3 (72-96h): Peak hepatotoxicity — markedly elevated AST/ALT (can exceed 10,000), coagulopathy, [[jaundice]], [[acute kidney injury]], [[hepatic encephalopathy]] | ||
**Fulminant hepatic failure: [[cerebral edema]], [[DIC]], [[multi-organ failure]], death | **Fulminant hepatic failure: [[cerebral edema]], [[DIC]], [[multi-organ failure]], death | ||
* | *Stage 4 (4-14 days): Recovery phase in survivors (hepatocytes regenerate) | ||
===Chronic/Repeated Supratherapeutic Ingestion=== | ===Chronic/Repeated Supratherapeutic Ingestion=== | ||
*More common than acute overdose in clinical practice | *More common than acute overdose in clinical practice | ||
*Presents with | *Presents with hepatotoxicity without early Stage 1 symptoms | ||
* | *Rumack-Matthew nomogram does NOT apply | ||
*Treat based on | *Treat based on APAP level + ALT elevation | ||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
| Line 42: | Line 42: | ||
==Evaluation== | ==Evaluation== | ||
*'''Serum APAP level''': draw at '''4 hours post-ingestion''' (or immediately if >4 hours) | *'''Serum APAP level''': draw at '''4 hours post-ingestion''' (or immediately if >4 hours) | ||
** | **Plot on Rumack-Matthew nomogram at time since ingestion | ||
** | **Treatment line: starts at 150 mcg/mL at 4 hours (US uses this; original line at 200) | ||
**Below treatment line = low risk; above = treat with NAC | **Below treatment line = low risk; above = treat with NAC | ||
* | *AST/ALT: may be normal initially; any elevation warrants NAC | ||
* | *INR/PT: coagulopathy = hepatic failure; INR is the best prognostic marker | ||
* | *BMP: creatinine (renal injury occurs in ~25% of severe cases), bicarbonate, glucose | ||
* | *Lipase, bilirubin, CBC | ||
* | *Salicylate level (coingestion screening) | ||
* | *Lactate: elevated lactate = poor prognosis | ||
* | *VBG/ABG: pH <7.30 after resuscitation = poor prognosis | ||
===King's College Criteria (Liver Transplant Referral)=== | ===King's College Criteria (Liver Transplant Referral)=== | ||
* | *Acetaminophen-induced ALF: | ||
** | **pH <7.30 after adequate fluid resuscitation (regardless of grade of encephalopathy) OR | ||
**All three: | **All three: INR >6.5, creatinine >3.4 mg/dL, and Grade III-IV hepatic encephalopathy | ||
* | *Consider early transfer to a liver transplant center | ||
==Management== | ==Management== | ||
===GI Decontamination=== | ===GI Decontamination=== | ||
* | *Activated charcoal 1 g/kg (max 50g) if within 1-2 hours of ingestion and patient is alert with protected airway | ||
*May benefit up to 4 hours post-ingestion | *May benefit up to 4 hours post-ingestion | ||
*Do NOT delay NAC for charcoal | *Do NOT delay NAC for charcoal | ||
===N-Acetylcysteine (NAC) — The Antidote=== | ===N-Acetylcysteine (NAC) — The Antidote=== | ||
* | *Give NAC if: | ||
**APAP level above treatment line on Rumack-Matthew nomogram | **APAP level above treatment line on Rumack-Matthew nomogram | ||
**Time of ingestion unknown and APAP level detectable | **Time of ingestion unknown and APAP level detectable | ||
** | **Elevated transaminases with history of APAP ingestion | ||
**Ingestion of | **Ingestion of > 150 mg/kg and level will not be available within 8 hours | ||
** | **Any doubt → give NAC (minimal side effects, potentially life-saving) | ||
====IV NAC Protocol (21-hour Protocol — Preferred)==== | ====IV NAC Protocol (21-hour Protocol — Preferred)==== | ||
* | *Loading dose: 150 mg/kg IV in 200 mL D5W over 60 minutes (or 15 minutes if used to be over 15 min) | ||
* | *Second infusion: 50 mg/kg IV in 500 mL D5W over 4 hours | ||
* | *Third infusion: 100 mg/kg IV in 1000 mL D5W over 16 hours | ||
* | *Total: 300 mg/kg over 21 hours | ||
*Anaphylactoid reactions (flushing, urticaria, bronchospasm) most common during loading dose | *Anaphylactoid reactions (flushing, urticaria, bronchospasm) most common during loading dose | ||
**Slow or pause infusion; treat with antihistamines/bronchodilators; '''do not stop NAC permanently''' | **Slow or pause infusion; treat with antihistamines/bronchodilators; '''do not stop NAC permanently''' | ||
====Oral NAC Protocol (72-hour)==== | ====Oral NAC Protocol (72-hour)==== | ||
* | *Loading dose: 140 mg/kg PO | ||
* | *Maintenance: 70 mg/kg PO every 4 hours × 17 additional doses | ||
* | *Total: 1,330 mg/kg over 72 hours | ||
*Mixed with cola or juice to improve palatability | *Mixed with cola or juice to improve palatability | ||
*If patient vomits within 1 hour of dose, | *If patient vomits within 1 hour of dose, repeat the dose | ||
====Two-Bag Modified Prescott Protocol==== | ====Two-Bag Modified Prescott Protocol==== | ||
| Line 93: | Line 93: | ||
===When to Stop NAC=== | ===When to Stop NAC=== | ||
* | *APAP level undetectable, AST/ALT normalizing/improving, INR ≤1.3, clinically well | ||
*If | *If AST/ALT still elevated or INR elevated: continue NAC beyond standard protocol | ||
===Fulminant Hepatic Failure=== | ===Fulminant Hepatic Failure=== | ||
* | *Continue IV NAC indefinitely (has benefit even in established liver failure) | ||
* | *Contact liver transplant center early | ||
*Manage: coagulopathy (FFP only if active bleeding), [[cerebral edema]] (elevate HOB, hypertonic saline, mannitol), [[hypoglycemia]], [[infection]], [[electrolyte imbalances]] | *Manage: coagulopathy (FFP only if active bleeding), [[cerebral edema]] (elevate HOB, hypertonic saline, mannitol), [[hypoglycemia]], [[infection]], [[electrolyte imbalances]] | ||
==Disposition== | ==Disposition== | ||
*'''Admit''' if NAC initiated, elevated transaminases, or altered mental status | *'''Admit''' if NAC initiated, elevated transaminases, or altered mental status | ||
* | *ICU for evidence of liver failure (coagulopathy, encephalopathy, acidosis, renal failure) | ||
* | *Consider discharge if: | ||
**APAP level below treatment line at ≥4 hours post-ingestion | **APAP level below treatment line at ≥4 hours post-ingestion | ||
**Normal AST/ALT, INR, creatinine | **Normal AST/ALT, INR, creatinine | ||
**4-6 hour observation complete | **4-6 hour observation complete | ||
**Psychiatric evaluation for intentional ingestions | **Psychiatric evaluation for intentional ingestions | ||
* | *Poison control: 1-800-222-1222 | ||
==See Also== | ==See Also== | ||
Latest revision as of 09:29, 22 March 2026
Background
- Most common cause of acute liver failure in the United States and UK
- Found in >600 OTC and prescription products (Tylenol, Percocet, Vicodin, NyQuil, etc.)
- Therapeutic dose: 10-15 mg/kg per dose (max 4g/day in adults; 2g/day in chronic alcoholics)
- Toxic dose: >150 mg/kg (single ingestion) or > 7.5 g total in adults
- Mechanism:
- Normal metabolism: 90% glucuronidation/sulfation → nontoxic → renally excreted
- ~5% oxidized by CYP2E1 → NAPQI (toxic metabolite) → detoxified by glutathione
- In overdose: glucuronidation/sulfation saturated → excess NAPQI production → glutathione depletion → hepatocellular necrosis
- N-acetylcysteine (NAC) is a glutathione precursor and is nearly 100% effective when given within 8 hours of ingestion[1]
Risk Factors for Enhanced Toxicity
- Chronic alcohol use (CYP2E1 induction + depleted glutathione stores)
- Fasting / malnutrition (depleted glutathione)
- CYP2E1 inducers: isoniazid, phenobarbital, carbamazepine, rifampin
- Lower threshold for treatment in these patients
Clinical Features
Four Stages of Toxicity
- Stage 1 (0-24h): Often asymptomatic or nonspecific (nausea, vomiting, anorexia, diaphoresis)
- Stage 2 (24-72h): RUQ pain, elevated transaminases, rising INR; may appear to improve clinically
- Stage 3 (72-96h): Peak hepatotoxicity — markedly elevated AST/ALT (can exceed 10,000), coagulopathy, jaundice, acute kidney injury, hepatic encephalopathy
- Fulminant hepatic failure: cerebral edema, DIC, multi-organ failure, death
- Stage 4 (4-14 days): Recovery phase in survivors (hepatocytes regenerate)
Chronic/Repeated Supratherapeutic Ingestion
- More common than acute overdose in clinical practice
- Presents with hepatotoxicity without early Stage 1 symptoms
- Rumack-Matthew nomogram does NOT apply
- Treat based on APAP level + ALT elevation
Differential Diagnosis
- Viral hepatitis
- Alcoholic hepatitis
- Other drug-induced hepatitis
- Ischemic hepatitis (shock liver)
- Wilson disease (acute presentation)
- Amanita phalloides (mushroom) poisoning
- Salicylate toxicity
- Other ingestions causing liver failure
Evaluation
- Serum APAP level: draw at 4 hours post-ingestion (or immediately if >4 hours)
- Plot on Rumack-Matthew nomogram at time since ingestion
- Treatment line: starts at 150 mcg/mL at 4 hours (US uses this; original line at 200)
- Below treatment line = low risk; above = treat with NAC
- AST/ALT: may be normal initially; any elevation warrants NAC
- INR/PT: coagulopathy = hepatic failure; INR is the best prognostic marker
- BMP: creatinine (renal injury occurs in ~25% of severe cases), bicarbonate, glucose
- Lipase, bilirubin, CBC
- Salicylate level (coingestion screening)
- Lactate: elevated lactate = poor prognosis
- VBG/ABG: pH <7.30 after resuscitation = poor prognosis
King's College Criteria (Liver Transplant Referral)
- Acetaminophen-induced ALF:
- pH <7.30 after adequate fluid resuscitation (regardless of grade of encephalopathy) OR
- All three: INR >6.5, creatinine >3.4 mg/dL, and Grade III-IV hepatic encephalopathy
- Consider early transfer to a liver transplant center
Management
GI Decontamination
- Activated charcoal 1 g/kg (max 50g) if within 1-2 hours of ingestion and patient is alert with protected airway
- May benefit up to 4 hours post-ingestion
- Do NOT delay NAC for charcoal
N-Acetylcysteine (NAC) — The Antidote
- Give NAC if:
- APAP level above treatment line on Rumack-Matthew nomogram
- Time of ingestion unknown and APAP level detectable
- Elevated transaminases with history of APAP ingestion
- Ingestion of > 150 mg/kg and level will not be available within 8 hours
- Any doubt → give NAC (minimal side effects, potentially life-saving)
IV NAC Protocol (21-hour Protocol — Preferred)
- Loading dose: 150 mg/kg IV in 200 mL D5W over 60 minutes (or 15 minutes if used to be over 15 min)
- Second infusion: 50 mg/kg IV in 500 mL D5W over 4 hours
- Third infusion: 100 mg/kg IV in 1000 mL D5W over 16 hours
- Total: 300 mg/kg over 21 hours
- Anaphylactoid reactions (flushing, urticaria, bronchospasm) most common during loading dose
- Slow or pause infusion; treat with antihistamines/bronchodilators; do not stop NAC permanently
Oral NAC Protocol (72-hour)
- Loading dose: 140 mg/kg PO
- Maintenance: 70 mg/kg PO every 4 hours × 17 additional doses
- Total: 1,330 mg/kg over 72 hours
- Mixed with cola or juice to improve palatability
- If patient vomits within 1 hour of dose, repeat the dose
Two-Bag Modified Prescott Protocol
- Some centers use a simplified 2-bag protocol: 200 mg/kg IV over 4 hours then 100 mg/kg IV over 16 hours
- Lower rate of anaphylactoid reactions[2]
When to Stop NAC
- APAP level undetectable, AST/ALT normalizing/improving, INR ≤1.3, clinically well
- If AST/ALT still elevated or INR elevated: continue NAC beyond standard protocol
Fulminant Hepatic Failure
- Continue IV NAC indefinitely (has benefit even in established liver failure)
- Contact liver transplant center early
- Manage: coagulopathy (FFP only if active bleeding), cerebral edema (elevate HOB, hypertonic saline, mannitol), hypoglycemia, infection, electrolyte imbalances
Disposition
- Admit if NAC initiated, elevated transaminases, or altered mental status
- ICU for evidence of liver failure (coagulopathy, encephalopathy, acidosis, renal failure)
- Consider discharge if:
- APAP level below treatment line at ≥4 hours post-ingestion
- Normal AST/ALT, INR, creatinine
- 4-6 hour observation complete
- Psychiatric evaluation for intentional ingestions
- Poison control: 1-800-222-1222
See Also
References
- Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med. 2008;359(3):285-292. PMID 18635433
- Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol. 2002;40(1):3-20. PMID 11990202
- Chun LJ, et al. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol. 2009;43(4):342-349. PMID 19169150
